FDA RAISES FINANCIAL DISCLOSURE THRESHOLD OF PAYMENTS TO INVESTIGATORS TO $25,000; LESS THAN 10% OF ALL APPLICATIONS WILL NEED DISCLOSURE, AGENCY PREDICTS
FDA has raised the threshold for disclosure of payments to investigators by study sponsors from $5,000 to $25,000 in the agency's final rule on financial disclosures by clinical investigators. The rule was published in the Feb. 2 Federal Register.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth